Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy

Rhea-AI Summary

Solid Biosciences (Nasdaq: SLDB) will present its largest scientific program at the 29th ASGCT Annual Meeting in Boston, May 11–15, 2026. The company will deliver 16 presentations (5 oral, 11 posters) covering clinical updates, next-generation delivery, capsid engineering and scalable AAV manufacturing.

AI-generated analysis. Not financial advice.

News Market Reaction – SLDB

+2.98%

1 alert

+2.98% News Effect

+$20M Valuation Impact

$693.81M Market Cap

1.52K Volume

On the day this news was published, SLDB gained 2.98%, reflecting a moderate positive market reaction. This price movement added approximately $20M to the company's valuation, bringing the market cap to $693.81M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Oral presentations: 5 presentations Poster presentations: 11 posters Total Solid-led talks: 16 presentations +5 more

8 metrics

Oral presentations 5 presentations Solid’s scientific program at 2026 ASGCT

Poster presentations 11 posters Solid’s scientific program at 2026 ASGCT

Total Solid-led talks 16 presentations Largest scientific program for the company at ASGCT 2026

ASGCT meeting dates May 11–15, 2026 29th Annual Meeting in Boston, MA

Current share price $7.05 Pre-news trading level with -5.37% 24h change

52-week high $8.8661 SLDB trades below this level pre-announcement

Market capitalization $733,178,914 Equity value prior to ASGCT news

Today's volume 1,131,886 shares 1.24x the 20-day average of 913,356 shares

Market Reality Check

Price: $6.50 Vol: Volume 1,131,886 shares i...

normal vol

$6.50 Last Close

Volume Volume 1,131,886 shares is at 1.24x the 20-day average of 913,356, indicating elevated trading interest ahead of the ASGCT meeting. normal

Technical Shares at $7.05 are trading above the 200-day MA of $6.13, despite a -5.37% move over the last 24 hours.

Peers on Argus

SLDB fell -5.37% alongside biotech peers: LXRX -6.63%, ALMS -4.23%, AURA -3.03%,...

SLDB fell -5.37% alongside biotech peers: LXRX -6.63%, ALMS -4.23%, AURA -3.03%, DMAC -2.93%, and FULC -2.26%, indicating a sector-wide downward bias despite the company-specific ASGCT update.

Historical Context

5 past events · Latest: Apr 28 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Apr 28	Orphan designation	Positive	-0.7%	EU Orphan Drug designation for SGT-003 in Duchenne muscular dystrophy.
Apr 07	Investor conferences	Neutral	+0.0%	Participation in Needham and Piper Sandler investor conferences and webcasts.
Mar 19	Earnings and update	Neutral	-1.3%	Q4/FY25 results with SGT-003 progress and cash runway into H1 2028.
Mar 11	Clinical update	Positive	-5.7%	Positive interim Phase 1/2 INSPIRE DUCHENNE data showing robust expression and biomarkers.
Mar 06	Private placement	Neutral	+20.3%	Approximately $240M oversubscribed private placement financing for pipeline development.

Pattern Detected

Recent history shows SLDB often trading down on positive clinical and regulatory updates, while an oversubscribed private placement coincided with a strong gain, suggesting reactions not always aligned with fundamental news tone.

Recent Company History

Over the last few months, SLDB reported multiple milestones, including a Mar 11 positive interim Phase 1/2 INSPIRE DUCHENNE update and a Mar 19 earnings release highlighting clinical progress and cash runway. The Mar 6 oversubscribed private placement drove a strong gain, while the Apr 28 EU Orphan Drug designation for SGT-003 and conference participation news had limited or negative price impact. Today’s ASGCT program update continues this pattern of scientific momentum.

Regulatory & Risk Context

Active S-3 Shelf · $240.0 million

Shelf Active

Active S-3 Shelf Registration 2026-03-19

$240.0 million registered capacity

An effective S-3 from Mar 19, 2026 registers 42,780,739 shares for resale tied to the March 2026 private placement. Proceeds from these secondary sales go to selling stockholders, not the company, and usage_count is 0, indicating no takedowns yet.

Market Pulse Summary

This announcement underscores Solid Biosciences’ expanding scientific footprint, with 16 company-led...

Analysis

This announcement underscores Solid Biosciences’ expanding scientific footprint, with 16 company-led presentations at ASGCT 2026 spanning clinical updates, novel AAV capsids and scalable manufacturing. Recent history shows continued regulatory and clinical progress, along with strengthened funding. Investors may monitor how data from SGT-003, SGT-212 and POLARIS-101™ evolve, how the registered 42,780,739 resale shares are used, and how future regulatory filings and trial updates develop.

Key Terms

phase 1/2, gene therapy, aav, capsid, +4 more

8 terms

phase 1/2 medical

"Update on the INSPIRE DUCHENNE Phase 1/2 Study of the Next-Generation..."

Phase 1/2 is a combined early-stage clinical trial that first tests a new drug or treatment for safety and the right dose, then quickly expands to check if it shows any signs of working in patients. For investors, results from a Phase 1/2 study offer an early read on both risk and potential reward—like a prototype test that both confirms a product won’t harm users and suggests whether it could sell—helping guide valuation and development decisions.

gene therapy medical

"microdystrophin Gene Therapy Candidate SGT-003 for Duchenne Muscular..."

Gene therapy is a medical technique that involves altering or replacing faulty genes in a person's cells to treat or prevent disease. It is considered a promising area of innovation because it has the potential to provide long-term or even permanent solutions to genetic conditions. For investors, advancements in gene therapy can signal opportunities in biotech companies and emerging treatments with significant growth potential.

aav medical

"A Novel Investigational AAV FXN Gene Therapy (SGT-212) for the Treatment..."

AAV is a small, generally harmless virus repurposed by researchers as a delivery vehicle to insert therapeutic genes into human cells; think of it as a postal service that carries corrective DNA to specific tissues. Investors pay attention because AAV-based treatments can offer durable, potentially one-time cures that command high prices, but they also carry development, manufacturing and regulatory risks that can sharply influence a biotech company’s value.

capsid medical

"next-generation CapsidPresentation ID: 3385Presenter: Patrick Gonzalez..."

A capsid is the protein shell that encases a virus’s genetic material, like the hard case around a fragile object. For investors, the capsid matters because its shape and chemistry determine how a virus or viral vector behaves—affecting vaccine effectiveness, gene therapy delivery, immune reactions, manufacturing complexity, and related patents, all of which can influence the commercial prospects and regulatory path of biotech products.

neutralizing antibodies medical

"tissues in the Presence of Neutralizing Antibodies Presentation ID: 3397..."

Neutralizing antibodies are immune proteins that attach to a virus or toxin and stop it from entering and damaging cells, effectively disarming the threat. For investors, measurements showing strong neutralizing activity can signal that a vaccine or treatment is likely to prevent disease, which influences clinical success, regulatory approvals, market demand and potential sales. Think of them as locks that keep a burglar out rather than alarms that merely report a break-in.

pharmacokinetic medical

"Title: Novel Pharmacokinetic Effects of POLARIS-101™ (AAV-SLB101)..."

Pharmacokinetic describes how a drug moves through and leaves the body — how it is absorbed, spread to tissues, broken down and excreted — like tracking a package from pickup to delivery and disposal. For investors, these properties determine effective dose, safety risks, how often a medicine must be taken, and how reliably it works, which in turn influence clinical trial success, regulatory approval chances, production complexity and a drug’s commercial value.

smrt sequencing technical

"Identifying Sources of Library Preparation Artifacts in AAV Vectors with SMRT Sequencing..."

SMRT sequencing is a DNA-reading technology that watches individual DNA molecules being copied in real time, producing long, continuous reads and often detecting chemical marks on the DNA. Think of it like reading a whole book aloud in one go rather than piecing together shredded pages—this makes complex regions easier to resolve. For investors, it matters because technologies that deliver faster, more accurate genetic information can drive demand in research, diagnostics and drug development, shaping revenue potential and competitive positions in biotech markets.

vector genome medical

"Impact of Genome Size and Sequence Composition on AAV Vector Genome Integrity..."

The vector genome is the DNA or RNA sequence packaged inside a delivery vehicle used in gene therapies and vaccines; think of it as the instruction manual placed inside a sealed courier box that tells cells what protein to make or how to behave. Investors care because the exact content and design affect how well a treatment works, its safety, regulatory review, manufacturing complexity and intellectual property, all of which drive clinical and commercial value.

AI-generated analysis. Not financial advice.

- Solid Biosciences delivers its largest scientific program at the 2026 ASGCT Annual Meeting with 5 oral presentations and 11 posters - 

CHARLESTOWN, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that multiple abstracts have been accepted for presentation at the upcoming 29^th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 11-15, 2026, in Boston, MA.

Solid Biosciences will deliver its largest number of presentations for the Company, reflecting the growing breadth and depth of Solid’s scientific efforts spanning clinical development, next-generation delivery technologies, capsid engineering and scalable manufacturing.

“With 16 Solid-led presentations, ASGCT 2026 marks an important meeting for the Company and reflects our growing leadership in next-generation precision genetic medicine,” said Bo Cumbo, President and Chief Executive Officer of Solid Biosciences. “The number and diversity of presentations we will be sharing underscore how far our organization has progressed in three short years, in addition to the scientific rigor we’re applying across discovery, development, manufacturing and clinical translation. From advanced platform and delivery technology engineering to updates from our clinical programs, this body of work reflects both the ambition of our team and the increasing maturity of our science.”

Oral Presentations

1. Title: Update on the INSPIRE DUCHENNE Phase 1/2 Study of the Next-Generation Microdystrophin Gene Therapy Candidate SGT-003 for Duchenne Muscular Dystrophy
   Session: In vivo clinical trials in eye and muscle disorders
   Presentation ID: 502
   Date/Time: May 15, 3:30pm ET
   Presenter: Kevin Flanigan, MD, Advisor Consultant & Researcher, Nationwide Children’s Hospital and Principal Investigator in the Phase 1/2 INSPIRE DUCHENNE clinical trial
2. Title: Efficacy and Safety of a Novel Investigational AAV FXN Gene Therapy (SGT-212) for the Treatment of Friedreich’s Ataxia
   Session: Neurologic diseases V
   Presentation ID: 353
   Date/Time: May 14, 10:30am ET
   Presenter: Brandon Chan, PhD, Discovery & Translational Development, Scientific Lead
3. Title: Development and Implementation of a High Yield and Scalable Manufacturing Process for Adeno-Associated Virus (AAV) Production
   Session: Scale-up, scale-out, formulation, supply chains, quality, and logistics I
   Presentation ID: 246
   Date/Time: May 13, 4:00pm ET
   Presenter: Ben Wright, Vice President, Head of Process Development
4. Title: Boosting rAAV Yield in HEK293 Cells Through Multi-Mechanism Strategies
   Session: AAV transfection improvements: Scaling and titers
   Presentation ID: 320
   Date/Time: May 14, 10:30am ET
   Presenter: Xiaofei E, PhD, Director, Molecular Therapeutics
5. Title: Utilizing Machine Learning and Mechanistic Understanding to Appreciate the Impact of pH, Dissolved Oxygen, and pCO₂ on Upstream AAV Yield and Product Quality
   Session: AAV critical quality attributes
   Presentation ID: 263
   Date/Time: May 14, 8:00am ET
   Presenter: Neil Templeton, PhD, Director, Upstream Process Development

Poster Presentations

1. Title: Novel Pharmacokinetic Effects of POLARIS-101™ (AAV-SLB101), Solid Biosciences’ Rationally Designed, Next-Generation Capsid
   Presentation ID: 3385
   Presenter: Patrick Gonzalez, PhD, Vice President, Head of Clinical Science
2. Title: SGT-003 Gene Therapy Restores DAPC Stability and Improves Muscle Integrity in Duchenne Muscular Dystrophy
   Presentation ID: 2365
   Presenter: Jamie Marshall, PhD, Director and Scientific Lead, Discovery & Translational Development
3. Title: A Novel AAV Gene Therapy Strategy to Correct Calcium Dysregulation in Catecholaminergic Polymorphic Ventricular Tachycardia
   Presentation ID: 1429
   Presenter: Meghan Soustek-Kramer, PhD, Principal Scientist and Scientific Lead, Discovery & Translational Development
4. Title: Systemic Delivery of Human TNNT2 Gene Therapy Using the Novel Capsid POLARIS-101™ (AAV-SLB101) Improves Cardiac Function in the TNNT2 R141W Knock-in Mouse Model of Dilated Cardiomyopathy
   Presentation ID: 3430
   Presenter: Jamie Marshall, PhD, Director and Scientific Lead, Discovery & Translational Development
5. Title: Systemic Administration of a Rationally Engineered Vector (POLARIS-101™ [AAV-SLB101]) Leads to Successful Transduction of Non-Human Primate Tissues in the Presence of Neutralizing Antibodies
   Presentation ID: 3397
   Presenter: Kruti Patel, PhD, Associate Director and Scientific Lead, Discovery & Translational Development
6. Title: Lower POLARIS-101^TM (AAV-SLB101) Cross-Reactive Antibodies in Elevidys-Treated Patients
   Presentation ID: 3382
   Presenter: Marla Bazile, Principal Associate Scientist, R&D
7. Title: Small Molecule Induced G2/M Arrest Boosts Recombinant AAV Production and Preserves High Quality
   Presentation ID: 3146
   Presenter: Xiaofei E, PhD, Director, Molecular Therapeutics
8. Title: Impact of Genome Size and Sequence Composition on AAV Vector Genome Integrity
   Presentation ID: 2010
   Presenter: Jie Tan, PhD, Director, Predictive Sciences
9. Title: Connecting Changes in AAV Capsid Protein Charge Species to In Vitro Protein Expression
   Presentation ID: 2216
   Presenter: Jonathan Hill, PhD, Principal Scientist
10. Title: Impact of Full vs. Empty AAV Capsids on Vector Potency
    Presentation ID: 2221
    Presenter: Cristiano Vieira, PhD, Senior Scientist, Analytical
11. Title: Identifying Sources of Library Preparation Artifacts in AAV Vectors with SMRT Sequencing
    Presentation ID: 1219
    Presenter: Sarah Tong, Senior Associate Scientist, Analytical Development
    

Additionally, Armatus Bio will present a poster highlighting POLARIS-101™’s utility in Facioscapulohumeral muscular dystrophy (FSHD) animal models:

• Title: FSHD Gene Therapy Using Systemic Delivery of Therapeutic miRNAs and the Engineered AAV-SLB101 Capsid Corrects FSHD-associated Phenotypes at Lower Doses Than First Generation Vectors
• Presentation ID: 1500
• Presenter: Lindsay Wallace, PhD, Center for Gene Therapy, The Research Institute at Nationwide Children’s Hospital
  

About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future expectations, plans and prospects for the company; the ability to successfully achieve and execute on the company’s goals; anticipated benefits of and strategies and expectations for the company’s SGT-003, SGT-212 and SGT-501 programs; expectations for planned enrollment of its SGT-003, SGT-212 and SGT-501 programs; planned regulatory interactions and the potential approval pathways for SGT-003; and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” “working” and similar expressions. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the company’s ability to advance SGT-003, SGT-212, SGT-501, SGT-601 and other preclinical programs, capsid libraries and other enabling technologies on the timelines expected or at all; obtain and maintain necessary approvals from the FDA and other regulatory authorities; replicate in clinical trials positive results found in preclinical studies and early-stage clinical trials of the company’s product candidates; manufacture sufficient quantities of our drug product in a timely manner and maintain adequate supply to support our clinical development and potential commercialization; obtain, maintain or protect intellectual property rights related to its product candidates; replicate preliminary or interim data from clinicals trials in the final data of such trials; compete successfully with other companies that are seeking to develop Duchenne, FA, CPVT and other neuromuscular and cardiac treatments and gene therapies; manage expenses; and raise the substantial additional capital needed, on the timeline necessary, to continue development of SGT-003, SGT-212, SGT-501, SGT-601 and other candidates; achieve its other business objectives and continue as a going concern. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the company’s actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in the company’s most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the company’s views as of the date hereof and should not be relied upon as representing the company’s views as of any date subsequent to the date hereof. The company anticipates that subsequent events and developments will cause the company's views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so.

Solid Biosciences Investor Contact:
Nicole Anderson
Senior Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com

FAQ

What is Solid Biosciences presenting at ASGCT 2026 (SLDB)?

Solid Biosciences will present 16 Solid-led presentations at ASGCT 2026. According to the company, this includes 5 oral presentations and 11 posters spanning clinical updates, capsid POLARIS-101, manufacturing processes, and next-generation delivery technologies.

When and where will Solid Biosciences (SLDB) present the INSPIRE DUCHENNE update?

The INSPIRE DUCHENNE Phase 1/2 update will be presented on May 15, 3:30pm ET. According to the company, Kevin Flanigan will present clinical results for the SGT-003 microdystrophin gene therapy during the in vivo clinical trials session.

Which Solid Biosciences (SLDB) presentations cover POLARIS-101 capsid data?

Multiple posters report POLARIS-101 (AAV-SLB101) data, including pharmacokinetics and transduction in non-human primates. According to the company, topics include antibody cross-reactivity, cardiac delivery, and efficacy at lower doses versus first-generation vectors.

Does Solid Biosciences (SLDB) present manufacturing or process development findings at ASGCT?

Yes. Solid will present multiple process-focused talks on scalable AAV manufacturing and yield improvements. According to the company, sessions cover high-yield processes, HEK293 multi-mechanism yield strategies, and impacts of pH/DO/pCO2 on upstream quality.

How does Solid Biosciences (SLDB) describe the significance of its ASGCT 2026 program?

The company describes ASGCT 2026 as its largest scientific showing, reflecting expanded R&D breadth. According to the company, the program demonstrates progress across discovery, development, manufacturing and clinical translation with diverse technical and clinical updates.